Abbott Laboratories ROE 2006-2019 | ABT
Current and historical return on equity (ROE) values for Abbott Laboratories (ABT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Abbott Laboratories ROE for the three months ending March 31, 2019 was 17.39%.
| Abbott Laboratories ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2019-03-31 | $2.62B | $31.13B | 8.49% |
| 2018-12-31 | $2.37B | $30.72B | 7.64% |
| 2018-09-30 | $0.89B | $30.90B | 2.85% |
| 2018-06-30 | $0.93B | $30.77B | 2.95% |
| 2018-03-31 | $0.48B | $31.60B | 1.50% |
| 2017-12-31 | $0.48B | $31.10B | 1.51% |
| 2017-09-30 | $2.10B | $32.22B | 7.23% |
| 2017-06-30 | $1.17B | $31.79B | 4.46% |
| 2017-03-31 | $1.50B | $31.55B | 6.40% |
| 2016-12-31 | $1.40B | $20.72B | 6.73% |
| 2016-09-30 | $1.37B | $20.90B | 6.53% |
| 2016-06-30 | $2.28B | $20.80B | 10.82% |
| 2016-03-31 | $2.45B | $20.84B | 11.31% |
| 2015-12-31 | $4.42B | $21.33B | 20.18% |
| 2015-09-30 | $4.56B | $21.22B | 20.74% |
| 2015-06-30 | $4.52B | $23.13B | 20.14% |
| 2015-03-31 | $4.20B | $21.99B | 18.60% |
| 2014-12-31 | $2.28B | $21.64B | 9.95% |
| 2014-09-30 | $1.97B | $22.99B | 8.25% |
| 2014-06-30 | $2.40B | $23.70B | 9.96% |
| 2014-03-31 | $2.41B | $23.49B | 10.14% |
| 2013-12-31 | $2.58B | $25.27B | 10.94% |
| 2013-09-30 | $3.04B | $23.79B | 12.70% |
| 2013-06-30 | $4.02B | $22.43B | 16.22% |
| 2013-03-31 | $5.27B | $22.68B | 20.82% |
| 2012-12-31 | $5.96B | $26.81B | 22.93% |
| 2012-09-30 | $6.53B | $27.10B | 25.67% |
| 2012-06-30 | $4.89B | $24.57B | 19.69% |
| 2012-03-31 | $5.11B | $25.54B | 20.18% |
| 2011-12-31 | $4.73B | $24.53B | 18.84% |
| 2011-09-30 | $4.55B | $24.69B | 18.45% |
| 2011-06-30 | $5.14B | $26.47B | 21.54% |
| 2011-03-31 | $4.49B | $24.72B | 20.18% |
| 2010-12-31 | $4.63B | $22.77B | 21.71% |
| 2010-09-30 | $4.73B | $21.48B | 22.06% |
| 2010-06-30 | $5.31B | $20.00B | 24.84% |
| 2010-03-31 | $5.31B | $21.01B | 24.84% |
| 2009-12-31 | $5.75B | $23.19B | 27.87% |
| 2009-09-30 | $5.74B | $21.38B | 29.91% |
| 2009-06-30 | $5.35B | $19.92B | 28.61% |
| 2009-03-31 | $5.38B | $17.98B | 29.17% |
| 2008-12-31 | $4.88B | $17.52B | 26.45% |
| 2008-09-30 | $4.55B | $19.35B | 24.55% |
| 2008-06-30 | $4.18B | $18.96B | 23.76% |
| 2008-03-31 | $3.85B | $17.98B | 23.05% |
| 2007-12-31 | $3.61B | $17.82B | 22.87% |
| 2007-09-30 | $1.93B | $15.61B | 13.00% |
| 2007-06-30 | $1.93B | $15.33B | 12.99% |
| 2007-03-31 | $1.55B | $14.32B | 10.47% |
| 2006-12-31 | $1.72B | $14.05B | 11.58% |
| 2006-09-30 | $3.17B | $15.63B | 21.24% |
| 2006-06-30 | $3.13B | $15.19B | 21.50% |
| 2006-03-31 | $3.40B | $14.44B | 23.64% |
| 2005-12-31 | $3.37B | $14.42B | 23.56% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $151.296B | $30.578B |
| Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $135.350B | 19.33 |
| Stryker (SYK) | United States | $77.587B | 27.69 |
| Boston Scientific (BSX) | United States | $58.741B | 28.16 |
| Baxter (BAX) | United States | $42.165B | 26.58 |
| EssilorLuxottica Societe Anonyme (ESLOY) | France | $28.527B | 0.00 |
| Coloplast (CLPBY) | Denmark | $25.661B | 40.97 |
| Lonza Group Ag (LZAGY) | Switzerland | $25.304B | 0.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.194B | 16.19 |
| Terumo (TRUMY) | Japan | $22.193B | 25.52 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $19.113B | 0.00 |
| ResMed (RMD) | United States | $17.749B | 33.91 |
| Canopy Growth (CGC) | Canada | $12.652B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $12.175B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.194B | 48.74 |
| Aurora Cannabis (ACB) | Canada | $7.514B | 74.10 |
| William Demant Holdings (WILYY) | Denmark | $7.411B | 0.00 |
| Insulet (PODD) | United States | $7.236B | 527.17 |
| Hill-Rom Holdings (HRC) | United States | $7.121B | 21.59 |
| Perrigo (PRGO) | Ireland | $6.850B | 11.58 |
| GN STORE NORD (GNNDY) | Denmark | $6.409B | 32.73 |
| Haemonetics (HAE) | United States | $6.254B | 51.05 |
| ICU Medical (ICUI) | United States | $5.122B | 30.57 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.916B | 0.00 |
| Neogen (NEOG) | United States | $3.373B | 54.85 |
| NuVasive (NUVA) | United States | $2.987B | 24.39 |
| Hutchison China MediTech (HCM) | China | $2.906B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $2.848B | 0.00 |
| National Vision Holdings (EYE) | United States | $2.479B | 52.82 |
| Quidel (QDEL) | United States | $2.261B | 23.46 |
| Aphria (APHA) | $1.646B | 0.00 | |
| Cardiovascular Systems (CSII) | United States | $1.530B | 878.80 |
| Phibro Animal Health (PAHC) | United States | $1.212B | 18.16 |
| AtriCure (ATRC) | United States | $1.196B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.177B | 24.98 |
| NanoString Technologies (NSTG) | United States | $1.065B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $1.052B | 27.95 |
| PetIQ (PETQ) | United States | $1.008B | 24.49 |
| Quanterix (QTRX) | United States | $0.783B | 0.00 |
| Cerus (CERS) | United States | $0.769B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.758B | 21.26 |
| Omeros (OMER) | United States | $0.758B | 0.00 |
| MacroGenics (MGNX) | United States | $0.740B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.686B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.591B | 28.62 |
| Surmodics (SRDX) | United States | $0.533B | 77.45 |
| OraSure Technologies (OSUR) | United States | $0.522B | 24.06 |
| Meridian Bioscience (VIVO) | United States | $0.489B | 14.96 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.398B | 0.00 |
| Vapotherm (VAPO) | United States | $0.337B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.325B | 22.51 |
| BioLife Solutions (BLFS) | United States | $0.313B | 97.88 |
| Zynex (ZYXI) | United States | $0.242B | 24.90 |
| Cytosorbents (CTSO) | United States | $0.234B | 0.00 |
| Bovie Medical (APYX) | United States | $0.224B | 0.00 |
| Chimerix (CMRX) | United States | $0.184B | 0.00 |
| Owens & Minor (OMI) | United States | $0.178B | 3.77 |
| United Health Products (UEEC) | United States | $0.175B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.168B | 0.00 |
| Female Health (VERU) | United States | $0.143B | 0.00 |
| Fonar (FONR) | United States | $0.141B | 7.40 |
| Chembio Diagnostics (CEMI) | United States | $0.100B | 0.00 |
| United-Guardian (UG) | United States | $0.091B | 19.97 |
| InfuSystems Holdings (INFU) | United States | $0.088B | 0.00 |
| Surface Oncology (SURF) | United States | $0.076B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.066B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.057B | 19.58 |
| MRI INTERVENTNS (MRIC) | United States | $0.053B | 0.00 |
